← Leaderboards
Peter James Krause
University Of Connecticut Sch Of Med/Dnt
$2,079,888
Attributed
$2,999,119
Total exposure
17
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $670.4K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,999,119 · 17
By mechanism
R21$944,606 · 2
R01$709,982 · 1
M01$674,139 · 13
R56$670,392 · 1
Top collaborators
- Durland Fish2 shared
- Sukanya Narasimhan2 shared
- Alan G. Barbour1 shared
- Linda K Bockenstedt1 shared
Most similar at University Of Connecticut Sch Of Med/Dnt
Same institution · by research overlap
- Timothy J Sellati$4,424,053
- Justin D. Radolf$26,431,208
- Melissa J Caimano$3,921,700
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchPediatric AidsHuman Therapy EvaluationAids TherapyHiv InfectionsCombination ChemotherapyDrug Screening /EvaluationZidovudineChild (0-11)Antiaids AgentNevirapineLongitudinal Human StudyMother /Infant Health CareInfant Human (0-1 Year)LamivudineNewborn Human (0-6 Weeks)Female2'3'DideoxyinosineHuman Pregnant SubjectAntiviral AgentsChemopreventionAdolescence (12-20)Oral Administration
Grant awards (76)
Determining the Health Burden of Borrelia Miyamotoi with a Next-Gen Diagnostic Assay$261,608
R21 · FY2019 · AI · contact PI
Determining the Health Burden of Borrelia Miyamotoi with a Next-Gen Diagnostic Assay$209,375
R21 · FY2018 · AI · contact PI
Borrelia Miyamotoi Infection in Mice and Humans$670,392
R56 · FY2015 · AI
The Health Burden of A Recently Discovered Borrelia Spirochete$164,313
R21 · FY2012 · AI · contact PI
The Health Burden of A Recently Discovered Borrelia Spirochete$309,310
R21 · FY2011 · AI · contact PI
RECURRENT LYME DISEASE$59,151
M01 · FY2008 · RR · contact PI
RECURRENT LYME DISEASE$42,035
M01 · FY2007 · RR · contact PI
RECURRENT LYME DISEASE$143,993
M01 · FY2005 · RR
Health Burden of Co-Infecting Deer-Associated Zoonotic CNS Disease$187,021
M01 · FY2004 · RR
Recurrent Lyme Disease$21,778
M01 · FY2004 · RR
Human Babesiosis$191
M01 · FY2004 · RR
ACTG 316--PHASE III RNADOMIZED, BLINDED STUDY OF NEVIRAPINE$0
M01 · FY2002 · RR
ACTG 338--PHASE II ROLLING ARM MASTER PROTOCOL(PRAM) OF NOVEL ANTIRETROVIRAL$0
M01 · FY2002 · RR
ACTG 185--USE OF HIVIG FOR THE PREVENTION OF MATERNAL/FETAL HIV TRANSMISSION$0
M01 · FY2002 · RR
SAFETY AND TOLERANCE OF CHRONIC NEVIRAPINE DOSING IN HIV 1 INFECTED CHILDREN$0
M01 · FY2002 · RR
ACTG 219--PEDIATRIC LATE OUTCOMES PROTOCOL$0
M01 · FY2002 · RR
ACTG 366 NOVEL ANTIRETROVIRAL COMBINATIONS IN ADVANCED HIV DISEASE$0
M01 · FY2002 · RR
ACTG 377: NOVEL ANTIRETROVIRAL THERAPY IN STABLE HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
HEALTH BURDEN OF CO INFECTING DEER ASSOCIATED ZOONOTIC CNS DISEASE$0
M01 · FY2002 · RR
ACTG 247: EFFECT OF INCREASED CALORIC FORMULA ON GROWTH IN HIV INFECT$0
M01 · FY2002 · RR
HEALTH BURDERN OF COINFECTING DEER ASSOCIATED ZOONOSES$359,913
R01 · FY2001 · AI
SAFETY AND TOLERANCE OF CHRONIC NEVIRAPINE DOSING IN HIV 1 INFECTED CHILDREN$4,361
M01 · FY2001 · RR
ACTG 366 NOVEL ANTIRETROVIRAL COMBINATIONS IN ADVANCED HIV DISEASE$4,361
M01 · FY2001 · RR
ACTG 377: NOVEL ANTIRETROVIRAL THERAPY IN STABLE HIV INFECTED CHILDREN$4,361
M01 · FY2001 · RR
HEALTH BURDEN OF CO INFECTING DEER ASSOCIATED ZOONOTIC CNS DISEASE$4,361
M01 · FY2001 · RR
ACTG 247: EFFECT OF INCREASED CALORIC FORMULA ON GROWTH IN HIV INFECT$4,361
M01 · FY2001 · RR
ACTG 316--PHASE III RNADOMIZED, BLINDED STUDY OF NEVIRAPINE$4,361
M01 · FY2001 · RR
ACTG 338--PHASE II ROLLING ARM MASTER PROTOCOL(PRAM) OF NOVEL ANTIRETROVIRAL$4,361
M01 · FY2001 · RR
ACTG 219--PEDIATRIC LATE OUTCOMES PROTOCOL$4,361
M01 · FY2001 · RR
ACTG 185--USE OF HIVIG FOR THE PREVENTION OF MATERNAL/FETAL HIV TRANSMISSION$4,361
M01 · FY2001 · RR
HEALTH BURDEN OF CO INFECTING DEER ASSOCIATED ZOONOTIC CNS DISEASE$0
M01 · FY2001 · RR
ACTG 219--PEDIATRIC LATE OUTCOMES PROTOCOL$0
M01 · FY2001 · RR
ACTG 219--PEDIATRIC LATE OUTCOMES PROTOCOL$0
M01 · FY2001 · RR
SAFETY AND TOLERANCE OF CHRONIC NEVIRAPINE DOSING IN HIV 1 INFECTED CHILDREN$0
M01 · FY2001 · RR
SAFETY AND TOLERANCE OF CHRONIC NEVIRAPINE DOSING IN HIV 1 INFECTED CHILDREN$0
M01 · FY2001 · RR
ACTG 185--USE OF HIVIG FOR THE PREVENTION OF MATERNAL/FETAL HIV TRANSMISSION$0
M01 · FY2001 · RR
ACTG 185--USE OF HIVIG FOR THE PREVENTION OF MATERNAL/FETAL HIV TRANSMISSION$0
M01 · FY2001 · RR
ACTG 338--PHASE II ROLLING ARM MASTER PROTOCOL(PRAM) OF NOVEL ANTIRETROVIRAL$0
M01 · FY2001 · RR
ACTG 338--PHASE II ROLLING ARM MASTER PROTOCOL(PRAM) OF NOVEL ANTIRETROVIRAL$0
M01 · FY2001 · RR
ACTG 316--PHASE III RNADOMIZED, BLINDED STUDY OF NEVIRAPINE$0
M01 · FY2001 · RR
ACTG 316--PHASE III RNADOMIZED, BLINDED STUDY OF NEVIRAPINE$0
M01 · FY2001 · RR
ACTG 247: EFFECT OF INCREASED CALORIC FORMULA ON GROWTH IN HIV INFECT$0
M01 · FY2001 · RR
ACTG 247: EFFECT OF INCREASED CALORIC FORMULA ON GROWTH IN HIV INFECT$0
M01 · FY2001 · RR
HEALTH BURDEN OF CO INFECTING DEER ASSOCIATED ZOONOTIC CNS DISEASE$0
M01 · FY2001 · RR
ACTG 377: NOVEL ANTIRETROVIRAL THERAPY IN STABLE HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
ACTG 377: NOVEL ANTIRETROVIRAL THERAPY IN STABLE HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
ACTG 366 NOVEL ANTIRETROVIRAL COMBINATIONS IN ADVANCED HIV DISEASE$0
M01 · FY2001 · RR
ACTG 366 NOVEL ANTIRETROVIRAL COMBINATIONS IN ADVANCED HIV DISEASE$0
M01 · FY2001 · RR
HEALTH BURDERN OF COINFECTING DEER ASSOCIATED ZOONOSES$350,069
R01 · FY2000 · AI
ACTG 338--PHASE II ROLLING ARM MASTER PROTOCOL(PRAM) OF NOVEL ANTIRETROVIRAL$19,111
M01 · FY2000 · RR
ACTG 247: EFFECT OF INCREASED CALORIC FORMULA ON GROWTH IN HIV INFECT$19,111
M01 · FY2000 · RR
ACTG 377: NOVEL ANTIRETROVIRAL THERAPY IN STABLE HIV INFECTED CHILDREN$19,111
M01 · FY2000 · RR
ACTG 366 NOVEL ANTIRETROVIRAL COMBINATIONS IN ADVANCED HIV DISEASE$19,111
M01 · FY2000 · RR
ACTG 316--PHASE III RNADOMIZED, BLINDED STUDY OF NEVIRAPINE$19,111
M01 · FY2000 · RR
ACTG 219--PEDIATRIC LATE OUTCOMES PROTOCOL$19,111
M01 · FY2000 · RR
SAFETY AND TOLERANCE OF CHRONIC NEVIRAPINE DOSING IN HIV 1 INFECTED CHILDREN$19,111
M01 · FY2000 · RR
HEALTH BURDEN OF CO INFECTING DEER ASSOCIATED ZOONOTIC CNS DISEASE$19,111
M01 · FY2000 · RR
ACTG 185--USE OF HIVIG FOR THE PREVENTION OF MATERNAL/FETAL HIV TRANSMISSION$19,111
M01 · FY2000 · RR
ACTG 185--USE OF HIVIG FOR THE PREVENTION OF MATERNAL/FETAL HIV TRANSMISSION$4,361
M01 · FY2000 · RR
ACTG 185--USE OF HIVIG FOR THE PREVENTION OF MATERNAL/FETAL HIV TRANSMISSION$4,361
M01 · FY2000 · RR
ACTG 338--PHASE II ROLLING ARM MASTER PROTOCOL(PRAM) OF NOVEL ANTIRETROVIRAL$0
M01 · FY2000 · RR
ACTG 366 NOVEL ANTIRETROVIRAL COMBINATIONS IN ADVANCED HIV DISEASE$0
M01 · FY2000 · RR
ACTG 366 NOVEL ANTIRETROVIRAL COMBINATIONS IN ADVANCED HIV DISEASE$0
M01 · FY2000 · RR
SAFETY AND TOLERANCE OF CHRONIC NEVIRAPINE DOSING IN HIV 1 INFECTED CHILDREN$0
M01 · FY2000 · RR
ACTG 219--PEDIATRIC LATE OUTCOMES PROTOCOL$0
M01 · FY2000 · RR
SAFETY AND TOLERANCE OF CHRONIC NEVIRAPINE DOSING IN HIV 1 INFECTED CHILDREN$0
M01 · FY2000 · RR
ACTG 377: NOVEL ANTIRETROVIRAL THERAPY IN STABLE HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
ACTG 377: NOVEL ANTIRETROVIRAL THERAPY IN STABLE HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
ACTG 219--PEDIATRIC LATE OUTCOMES PROTOCOL$0
M01 · FY2000 · RR
HEALTH BURDEN OF CO INFECTING DEER ASSOCIATED ZOONOTIC CNS DISEASE$0
M01 · FY2000 · RR
HEALTH BURDEN OF CO INFECTING DEER ASSOCIATED ZOONOTIC CNS DISEASE$0
M01 · FY2000 · RR
ACTG 247: EFFECT OF INCREASED CALORIC FORMULA ON GROWTH IN HIV INFECT$0
M01 · FY2000 · RR
ACTG 247: EFFECT OF INCREASED CALORIC FORMULA ON GROWTH IN HIV INFECT$0
M01 · FY2000 · RR
ACTG 316--PHASE III RNADOMIZED, BLINDED STUDY OF NEVIRAPINE$0
M01 · FY2000 · RR
ACTG 316--PHASE III RNADOMIZED, BLINDED STUDY OF NEVIRAPINE$0
M01 · FY2000 · RR
ACTG 338--PHASE II ROLLING ARM MASTER PROTOCOL(PRAM) OF NOVEL ANTIRETROVIRAL$0
M01 · FY2000 · RR